Biotech Values

[biomaven0]

I'd add that inhibiting FLT3 in multiple trials has not to date lived up to expectations - partly it seems that levels of the FLT3 ligand increase, and this interferes with the inhibition.

It is possible that a very potent FLT3 inhibitor might work much better, so it certainly will be worth exploring whether pona has a role here. But the Ambit drug seems very potent as well.

Peter